TY - JOUR
T1 - Immunological activation following transcutaneous delivery of HR-gp100 protein
AU - Frankenburg, Shoshana
AU - Grinberg, Igor
AU - Bazak, Ziva
AU - Fingerut, Lena
AU - Pitcovski, Jacob
AU - Gorodetsky, Raphael
AU - Peretz, Tamar
AU - Spira, Ram M.
AU - Skornik, Yehuda
AU - Goldstein, Ronald S.
N1 - Funding Information:
This work was supported by the Chief Scientist of the Israel Ministry of Industry and Commerce, and by NIH grant 1 R21 CA114160-01A1 (to S.F.). We wish to thank Dr. Gerard Marx from Hapto Biotech for his help and advice.
PY - 2007/6/6
Y1 - 2007/6/6
N2 - Transcutaneous immunization aims at taking advantage of the skin's immune system for the purpose of immunoprotection. In the present study, we evaluated the potential of topical delivery of a recombinant melanoma protein, HR-gp100, derived from a shortened sequence of the native gp100 gene. The protein was applied on the skin, with and without the addition of two forms of heat labile enterotoxin (nLT and LTB). HR-gp100 fused to Haptide, a cell penetrating 20mer peptide (HR-gp100H) was also tested. Topical HR-gp100 and HR-gp100H application on the ears of mice elicited the production of specific antibodies, and transcutaneous delivery to intact human skin induced dose-dependent LC activation. nLT and LTB also activated LC, but did not further increase the activation induced by HR-gp100. These results show that HR-gp100, an antigenic tumor-derived protein, activates the immune system following transcutaneous delivery, as shown by both Langerhans cell activation and induction of antibody production.
AB - Transcutaneous immunization aims at taking advantage of the skin's immune system for the purpose of immunoprotection. In the present study, we evaluated the potential of topical delivery of a recombinant melanoma protein, HR-gp100, derived from a shortened sequence of the native gp100 gene. The protein was applied on the skin, with and without the addition of two forms of heat labile enterotoxin (nLT and LTB). HR-gp100 fused to Haptide, a cell penetrating 20mer peptide (HR-gp100H) was also tested. Topical HR-gp100 and HR-gp100H application on the ears of mice elicited the production of specific antibodies, and transcutaneous delivery to intact human skin induced dose-dependent LC activation. nLT and LTB also activated LC, but did not further increase the activation induced by HR-gp100. These results show that HR-gp100, an antigenic tumor-derived protein, activates the immune system following transcutaneous delivery, as shown by both Langerhans cell activation and induction of antibody production.
KW - Langerhans cells
KW - Melanoma
KW - Transcutaneous vaccination
UR - http://www.scopus.com/inward/record.url?scp=34248334248&partnerID=8YFLogxK
U2 - 10.1016/j.vaccine.2007.04.025
DO - 10.1016/j.vaccine.2007.04.025
M3 - ???researchoutput.researchoutputtypes.contributiontojournal.article???
C2 - 17493711
AN - SCOPUS:34248334248
SN - 0264-410X
VL - 25
SP - 4564
EP - 4570
JO - Vaccine
JF - Vaccine
IS - 23
ER -
